MedTrace Logo

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

NCT01163227 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2020-12-24

No results posted yet for this study

Summary

This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.

Conditions

  • Schizophrenia Disorders

Interventions

DRUG

Placebo (single and multiple doses)

DRUG

AQW051 2 mg (single and multiple doses)

DRUG

AQW051 15mg (single and multiple doses)

DRUG

AQW051 100mg (single dose), and 50mg (multiple doses)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163227 on ClinicalTrials.gov